CTOs on the Move

Melinta

www.melinta.com

 
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.melinta.com
  • 300 George Street Suite 301
    New Haven, CT USA 06511
  • Phone: 203.624.5606

Executives

Name Title Contact Details
Melinta Therapeutics
 Chief Technology Officer Profile

Funding

Melinta raised $67M on 06/10/2015

Similar Companies

Enko Chem

Enko discovers and develops novel products for farmers to protect their crops from pests and disease. Its proprietary technology platform represents a revolutionary approach to rapidly discover safe and economical solutions that are needed to ensure sustainable food production.

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.

Bolt Biotherapeutics

Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.

chemill Inc

chemill Inc is a Bothell, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santen

Santen Inc. is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.